Researchers found that childhood unpredictability provided additional information about mental health risk beyond conventional ACEs screening.

Lavengratinib increased annualized height velocity in 7 children with achondroplasia, but open-label phase 2 findings remain preliminary.

The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.

Suicide-related pediatric ED visits rose 74% from 2016 to 2022; about half occurred at EDs with lower pediatric volume, a national analysis found.

Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.

FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.

Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.